论文部分内容阅读
目的观察吉西他滨和奥沙利铂对老年非小细胞肺癌患者的治疗作用和不良反应。方法符合要求的非小细胞肺癌患者,大于65岁的30例为老年组,小于60岁的30例为对照组。以吉西他滨联合奥沙利铂进行化疗,对比两组患者的病例特征、疗效和不良反应。结果两组无进展生存期(PFS)、客观缓解率(ORR)和一年期生存率(1-year SR)差异均无统计学意义,老年组患者白细胞减少和血小板减少均较严重(P<0.05),贫血无明显区别。无严重肝肾功能损害发生。结论吉西他滨联合奥沙利铂是治疗晚期非小细胞肺癌老年患者的安全有效的方案。
Objective To observe the therapeutic effects and adverse reactions of gemcitabine and oxaliplatin in elderly patients with non-small cell lung cancer. Methods To meet the requirements of non-small cell lung cancer patients, more than 65-year-old 30 cases of elderly, less than 60-year-old 30 cases of control group. Chemotherapy with gemcitabine combined with oxaliplatin compared the characteristics of the two groups of patients, efficacy and adverse reactions. Results There was no significant difference in progression-free survival (PFS), objective response rate (ORR) and 1-year SR between the two groups, and severe leukopenia and thrombocytopenia in the elderly group (P < 0.05), anemia no significant difference. No serious liver and kidney dysfunction occurs. Conclusion Gemcitabine combined with oxaliplatin is a safe and effective treatment for elderly patients with advanced non-small cell lung cancer.